ICON Appoints Alan Morgan To Role Of Group President, Clinical Research Services
ICON plc (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of
outsourced development services to the pharmaceutical, biotechnology and
medical device industries, today announced the appointment of Mr.
ICON plc (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Mr. Alan Morgan to the position of Group President, Clinical Research Services. Mr. Morgan is currently Group President, ICON Early Phase and Laboratory Services, and prior to that was Chief Operating Officer of the ICON Clinical Research division, having joined ICON in 2006. Alan has over 20 years experience working in both the pharmaceutical and the CRO industries. Prior to joining ICON, he was Vice President and Global General Manager of the Phase II/IV business of MDS Pharma Services, and he has also held senior positions in Covance, Glaxo Wellcome and ICI Pharmaceuticals. ICON also announced that Ms Linda Meyerson has joined the company as Chief Operating Officer, ICON Clinical Research. Ms Meyerson will report directly to Mr. Morgan and brings over 30 years of pharmaceutical industry experience and drug development knowledge to the organisation. Prior to joining ICON, Ms Meyerson was Vice President, Global Clinical Operations for GlaxoSmithKline, having previously served in a similar global capacity for the Janssen Research Foundation and the RW Johnson Pharmaceutical Research Institute. ICON also announced that Dr. John Hubbard, the former Group President, Clinical Research Services, is leaving the organisation to take up a senior role in a leading global biopharmaceutical company. Commenting on the organisational changes, Mr. Peter Gray, CEO ICON plc said, "I would like to welcome Alan to his new role. He has been an outstanding member of our management team, and his deep knowledge of our clinical organisation and broad industry experience will be invaluable as we continue to develop our business." Mr Gray added, “We are also delighted to welcome Linda to our team. Her extensive global drug development experience will be a huge asset to the organisation. We are sorry to lose John Hubbard, and I would like to acknowledge his outstanding contribution to ICON and wish him every success in his new challenging role.”